Gensco Pharma
Gensco Pharma is a privately held Miami-based specialty pharmaceutical company that develops and commercializes prescription transdermal and topical products—including LidoDose, ColciGel, Astero, LiDORx, SpeedGel Rx, and the soon-to-launch RizaFilm migraine film—for physicians, podiatrists, and wound care specialists, distributed through U.S. national wholesalers and major pharmacy chains.
- Company typePrivate
- Founded2011
- HeadquartersDoral, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Gensco Pharma does
Gensco Pharma, LLC is a privately held specialty pharmaceutical company headquartered in Doral/Miami, Florida, founded around 2009–2011 and operating with 11–50 employees. The company develops, manufactures, and commercializes prescription transdermal and topical drug products—LidoDose, ColciGel, Astero, LiDORx, and SpeedGel Rx—targeting pain management, wound care, and acute inflammatory conditions. Its underlying technology is a proprietary transdermal drug-delivery platform built on micelle-forming vehicles combined with chemical penetration enhancers (CPEs), enabling drug flux through the stratum corneum at rates reportedly greater than 40% versus 1–5% for typical topical formulations; this is paired with the patented MDose metered-dose applicator that delivers precise, consistent pump doses. First-mover FDA approvals include ColciGel (2015) as the first transdermal treatment for acute gout flares and Astero (2016) as the first FDA-approved prescription combination drug-device hydrogel with Lidocaine 4%.
The company operates a sales-led, enterprise field-sales go-to-market targeting physicians, podiatrists, rheumatologists, and wound care specialists, supported by a Medical Advisory Board that includes Dr. James Andrews and Dr. Gary Myerson. U.S. distribution is anchored by the Big Three wholesalers (McKesson, Cardinal Health, Amerisource-Bergen), major chain pharmacies (Walgreens, CVS Pharmacy), group purchasing organizations, and specialty pharmacies. Revenue is generated primarily through prescription pharmaceutical sales, with selective licensing royalties (e.g., RizaFilm). Copay-assistance and cash-pay programs support patient access at the pharmacy counter.
In December 2018, Gensco partnered with IntelGenx to commercialize the RizaFilm/RizaPort oral dissolvable rizatriptan film for acute migraine in the United States (with China exclusivity), and in May 2025 it acquired global rights and intellectual property for these assets, positioning Q4 2025 as the planned U.S. migraine launch. Operating divisions include Gensco Diagnostics and Gensco Global, signaling adjacent-category and international commercial ambitions. Leadership is led by President and CEO Carlos Alfaras, supported by Executive Director of Medical Affairs Robert L. Wilbur. The company appears founder/management-owned with no disclosed institutional funding.
Gensco Pharma firmographics
Firmographics- Name
- Gensco Pharma
- Legal name
- Gensco Pharma LLC
- Website
- https://genscopharma.com
- Company type
- Private
- Founded year
- 2011
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Gensco Pharma is a privately held Miami-based specialty pharmaceutical company that develops and commercializes prescription transdermal and topical products—including LidoDose, ColciGel, Astero, LiDORx, SpeedGel Rx, and the soon-to-launch RizaFilm migraine film—for physicians, podiatrists, and wound care specialists, distributed through U.S. national wholesalers and major pharmacy chains.
- Ownership category
- akta.pro rank
Gensco Pharma industry classification
Industry- Product category
- Specialty Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Specialty Care Pharmaceuticals (HLAIAAAB)
- akta.pro secondary industries
- Pain Management & Anesthesiology Pharmaceuticals (HLAIAAAN), Dermatology & Aesthetics Pharmaceuticals (HLAIAAAK)
Keywords
Where Gensco Pharma is headquartered
LocationHeadquarters
- HQ city
- Doral
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
Gensco Pharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Personnel, Marketing or Sales, Technology or R&D, Supply Chain
Revenue model
- Prescription Pharmaceutical Sales: Revenue generated from manufacturing and selling prescription transdermal products including LidoDose, ColciGel, Astero, LiDORx, and SpeedGel Rx through pharmacy distribution channels including major chains, wholesalers, and specialty pharmacies. Products are sold as prescription medications to patients through healthcare providers.
- Licensing Royalties (RizaFilm): Gensco holds exclusive rights to commercialize RizaFilm in the US and pays royalty payments based on net profits to IntelGenx. Gensco also receives milestone payments upon FDA approval and product launch from the partnership.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | ColciGel pricing per treatment flare |
| Other | Pay-as-you-go | Astero copay savings program |
| Transaction based/ take rate | Pay-as-you-go | RIZAFILM royalty structure |
Go-to-market motion2 records
Distribution channels5 records
Marketing channels6 records
Gensco Pharma product offering
Product offeringCore offering
Gensco Pharma is a specialty pharmaceutical company that develops, manufactures, and commercializes prescription transdermal and topical drug products for pain management, inflammatory conditions, and wound care. Its portfolio includes lidocaine-based topical anesthetics (LidoDose, LiDORx), a transdermal colchicine gel for acute gout flares (ColciGel), a prescription hydrogel for painful wounds (Astero), and a non-NSAID pain and inflammation gel (SpeedGel Rx), all built on a proprietary metered-dose transdermal delivery platform. The company has also acquired global rights to RizaFilm, an oral dissolvable rizatriptan film for acute migraine.
Product overview
Gensco Pharma is a specialty pharmaceutical company specializing in prescription transdermal products for pain management and inflammatory conditions. The company's portfolio includes five core transdermal/topical products: LidoDose® (topical anesthetic), ColciGel® (first transdermal gout treatment), Astero® (FDA-approved hydrogel with lidocaine for wounds), LiDORx® (topical anesthetic for pain), and SpeedGel Rx® (non-NSAID pain treatment). The company has also acquired rights to RizaFilm® (oral dissolvable film for migraines). All products utilize the proprietary MDose® metered dose technology for precise dosing. Gensco Pharma focuses on innovative drug delivery systems that enable transdermal penetration of medications.
Differentiator
Problem solved
Functional benefit
Brands
- MDose: Patented topical metered dose applicator technology that dispenses exact and consistent dose of medication with every pump
- Gensco Diagnostics
- Gensco Global
Products and services
- LidoDose® Single-dose topical anesthetic and antiseptic formulated for preprocedural use by healthcare providers prior to minor procedures.
- ColciGel® First transdermal colchicine gel for acute gout flares; delivers colchicine directly to the site of inflammation with minimal systemic absorption, avoiding GI adverse effects associated with oral colchicine.
- Astero® First FDA-approved prescription combination drug-device hydrogel containing Lidocaine 4% HCl, providing moist wound healing and sustained topical anesthesia for painful wounds including diabetic foot ulcers, pressure ulcers, burns, and post-surgical incisions.
- LiDORx® Topical 3% lidocaine formulation that delivers fast, controlled pain relief at the site of application; demonstrated 3x greater drug movement across synthetic skin compared to typical topical lidocaine formulations.
- SpeedGel Rx® Non-NSAID topical transdermal gel for pain, inflammation, and bruising; provides targeted relief for post-operative pain, osteoarthritis, and musculoskeletal sprains and strains without systemic NSAID side effects.
Quantifiable outcome
- MDose technology reduces waste by 60% compared to standard tube application, with dosage accuracy of prescribed medication
- +6 more outcomes
Companies that use Gensco Pharma
Customer profileNamed customers3 records
Segments4 records
Ideal customer profiles4 records
Gensco Pharma technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Gensco Pharma partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- IntelGenx CorpcoreGensco Pharma partnered with IntelGenx to launch and commercialize RIZAFILM (US market name for RIZAPORT - Rizatriptan Oral Film) in the United States. Gensco received exclusive rights to commercialize the product in the US, with royalty payments to IntelGenx based on net profits. The agreement also grants Gensco exclusivity to develop, sell, distribute and fully commercialize products for the People's Republic of China. IntelGenx is eligible to receive milestone payments upon FDA approval and product launch.
Scale indicators5 records
Recent moves6 records
Expansion highlights5 records
Gensco Pharma competitors and assessment
Company assessmentDirect peers
- Pernix Therapeutics: Specialty pharma historically focused on pain, CNS and specialty categories with prescription transdermal/topical products. Comparable in size and specialty-pharma commercial positioning to Gensco.
- Noven Pharmaceuticals: Specialty transdermal patch developer (acquired by Hisamitsu). Directly comparable as a focused transdermal drug delivery company commercializing prescription patches for CNS and other indications — same delivery-platform DNA and specialty-pharma go-to-market as Gensco.
- BioDelivery Sciences International: Specialty pharma focused on pain and addiction therapies using novel delivery technologies including buccal film (Bunavail) and transdermal. Highly comparable specialty-pain portfolio with novel-delivery-tech positioning overlapping Gensco's franchise.
- Collegium Pharmaceutical: Specialty pharma focused on responsible pain management (Xtampza ER, Nucynta). Comparable as a small-cap specialty pharma commercializing differentiated pain products through physician-targeted sales and managed-care channels.
- Assertio Therapeutics: Specialty pharma with portfolio of non-opioid pain and neurology products. Comparable therapeutic focus on pain management with differentiated delivery formats and similar specialty-pharma commercial profile.
- IntelGenx Corp: Oral thin film technology developer and former RizaFilm partner. Highly comparable as the source of VersaFilm technology now fully acquired by Gensco; smaller-cap peer with overlapping oral-film/cns specialty pipeline.
Broad incumbents
- Hisamitsu Pharmaceutical: Japanese global leader in transdermal patches (Salonpas) and parent of Noven. Comparable as the dominant incumbent in the same transdermal delivery category Gensco operates in, with much broader geographic and product reach.
- Mallinckrodt Pharmaceuticals: Specialty pharma with significant topical/transdermal pain portfolio (lidocaine patches, topical NSAIDs). Comparable as a broader incumbent in the same transdermal pain category with overlapping therapeutic franchises.
- Viatris (Mylan Upjohn): Large generics and specialty pharma with significant transdermal patch portfolio. Comparable as a much larger incumbent competing in the same transdermal delivery space, especially relevant for RizaFilm generic-rizatriptan competition.
Emerging players
- Sorrento Therapeutics: Clinical-stage biopharma with specialty pain programs and topical/transdermal delivery development. Comparable as a smaller specialty-pharma with parallel emerging-pain and novel-delivery development focus.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Gensco Pharma social profiles
Digital presenceGensco Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Gensco Pharma leadership team
Management profileNumber of profiles
Profiles5 records
Gensco Pharma funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Gensco Pharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Gensco Pharma
What does Gensco Pharma do?
Gensco Pharma is a specialty pharmaceutical company that develops, manufactures, and commercializes prescription transdermal and topical drug products for pain management, inflammatory conditions, and wound care. Its portfolio includes lidocaine-based topical anesthetics (LidoDose, LiDORx), a transdermal colchicine gel for acute gout flares (ColciGel), a prescription hydrogel for painful wounds (Astero), and a non-NSAID pain and inflammation gel (SpeedGel Rx), all built on a proprietary metered-dose transdermal delivery platform. The company has also acquired global rights to RizaFilm, an oral dissolvable rizatriptan film for acute migraine.
Is Gensco Pharma a public or private company?
Gensco Pharma is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Gensco Pharma founded?
Gensco Pharma was founded in 2011. It employs 11 to 50 people.
Where is Gensco Pharma based?
Gensco Pharma is headquartered in Doral, United States, in the North America region.
How does Gensco Pharma make money?
Two revenue lines are on record. Prescription Pharmaceutical Sales are the primary driver. The others are licensing Royalties (RizaFilm).
Who are Gensco Pharma's main competitors?
Direct peers on record are Pernix Therapeutics, Noven Pharmaceuticals, BioDelivery Sciences International, Collegium Pharmaceutical, Assertio Therapeutics and IntelGenx Corp. Broad incumbents are Hisamitsu Pharmaceutical, Mallinckrodt Pharmaceuticals and Viatris (Mylan Upjohn). Sorrento Therapeutics is listed as an emerging player.
Does Gensco Pharma have an API?
No public API is recorded for Gensco Pharma.
What industry is Gensco Pharma in?
Gensco Pharma's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAB, Specialty Care Pharmaceuticals, with a secondary code of HLAIAAAN, Pain Management & Anesthesiology Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.